Parkinson Disease

Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic, provided comment on a recently published randomized controlled trial assessing the therapeutic potential of an augmented reality program for postural instability and gait dysfunction in Parkinson disease.

After Supernus met with the FDA earlier this year, the company believes it has addressed the agency’s requests mentioned in its complete response letter delivered in October 2022.

The senior vice president and chief scientific officer of the Parkinson’s Foundation discussed a recently published Medicare claims analysis that highlighted significant issues with access to proper care for patients with Parkinson disease. [WATCH TIME: 4 minutes]

The senior vice president and chief scientific officer of the Parkinson’s Foundation provided perspective on the reasons for the lack of mental health specialists in Parkinson disease care and the complexities behind treating depression. [WATCH TIME: 4 minutes]

The professor of neurology and resident program director at MedStar Georgetown University Hospital discussed how Parkinson disease motor fluctuations are managed amid new, novel technologies incorporated in the field. [WATCH TIME: 4 minutes]

Although research supports the use of physical therapy as an effective treatment for Parkinson disease, implementation factors including type, timing, frequency, and durability of outcomes remain mainly untouched.

Virginia Gao, MD, PhD, a movement disorders fellow at Weill Cornell Medicine, discussed several topics related to the use of biomarkers in the prodromal stages of neurodegenerative disorders like Parkinson disease.

The movement disorder specialist at Cambridge University Hospitals NHS Foundation Trust talked about a patient with treatment-resistant Parkinson disease who experienced significant improvement in motor symptoms after using a vibrational therapy. [WATCH TIME: 8 minutes]

Because its gut-acting and gut-restricted, the safety profile of DGX-001 was considered advantageous in comparison to traditional neuropsychiatric therapies.

The fourth-generation deep brain stimulation system is designed to treat the symptoms of Parkinson disease and essential tremor by delivering targeted electrical stimulation via surgically-implanted leads in the brain connected to an implantable pulse generators.

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the evolution of treatment for Parkinson disease and the new promising therapies patients may seen over the coming years. [WATCH TIME: 3 minutes]

Reasons behind the CRL were not related to efficacy and do not impact Amneal’s 2023 financial guidance, which did not include IPX203 revenues.

In patients with early Parkinson disease, results showed that UB-312 was generally safe and well-tolerated, which supports the advancement of the vaccine into further clinical development.

The assistant professor of occupational therapy at the New York Institute of Technology talked about educating patients with Parkinson disease about the importance of maintaining social participation for cognitive function at ATMRD 2023. [WATCH TIME: 5 minutes]

The nurse practitioner in the movement disorder division at Georgetown University Hospital discussed differences in available therapies for movement disorders versus multiple sclerosis and using a chronic care management model in Parkinson disease. [WATCH TIME: 5 minutes]

Patients with Parkinson disease who were inpatients had significant impacts on their length of stay, readmissions, and morbidity after hospitalization when administered contraindicated medications.

At AMTRD 2023, the graduate research assistant at Brown University talked about the prevalence of rapidly progressive dementia and cognition fluctuation in Parkinson disease as well as the effects of treatments for the condition. [WATCH TIME: 5 minutes]

Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida, provided insight on the therapeutic potential of IPX203, and why it adds flexibility to the treatment of Parkinson disease.

At AMTRD 2023, the movement disorder neurologist at the Parkinson’s Disease and Movement Disorder Center of Silicon Valley talked about the current care landscape for Parkinson disease and improving on-time for patients experiencing OFF periods. [WATCH TIME: 5 minutes]

In a recent survey, a group of advanced practice providers recognized the importance and considered the emotional impact of the unexpected return of symptoms on the life of a patient with Parkinson disease.

Pooled results of a post hoc analysis from phase 3 studies of amantadine (Gocovri; Supernus) suggest that the therapy offers increased good ON time, and in intervals that are more predictable for patients, compared with placebo.

The companies have noted that the decision was not made because of safety or efficacy data, but to refocus efforts on the ongoing phase 2b LUMA trial of BIIB122.

The clinical professor in the department of neurology at the University of California, San Francisco, emphasized the need to restrict trichloroethylene availability and the challenges in studying environmental factors associated with Parkinson disease. [WATCH TIME: 4 minutes]

The clinical professor in the Department of Neurology at the University of California, San Francisco, talked about the association between contaminated water and Parkinson disease. [WATCH TIME: 6 minutes]

The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided perspective on the difficulties with testing agents for Parkinson disease psychosis, and the future outlook of treating the symptom. [WATCH TIME: 4 minutes]

Study shows that digital devices can provide objective and real-world measures of Parkinson disease, capturing key motor and nonmotor features of for early diagnosis of the neurodegenerative disorder.

The director of the James J. and Joan A. Gardner Family Center discussed data from the phase 3 BouNDless trial assessing a continuous, subcutaneous levodopa/carbidopa delivery system for patients with Parkinson disease experiencing motor fluctuations. [WATCH TIME: 3 minutes]

The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute discussed the future of treating Parkinson disease psychosis, and potential ways to lower risk of poor long-term outcomes. [WATCH TIME: 3 minutes]

A recent published study highlighted the importance of environmental risk factors for Parkinson disease, such as exposure to trichloroethylene and other volatile organic compounds.

Marcelo Bigal, MD, PhD, chief executive officer of Ventus Therapeutics, talked about the relationship between inflammation and neurodegeneration in Parkinson disease, and the importance of targeting NLRP3.